Enochian Biosciences, Inc. (ENOB): Price and Financial Metrics


Enochian Biosciences, Inc. (ENOB): $6.26

0.23 (+3.81%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENOB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ENOB Stock Price Chart Interactive Chart >

Price chart for ENOB

ENOB Price/Volume Stats

Current price $6.26 52-week high $13.78
Prev. close $6.03 52-week low $3.70
Day low $5.96 Volume 146,600
Day high $6.39 Avg. volume 214,707
50-day MA $7.41 Dividend yield N/A
200-day MA $7.58 Market Cap 331.47M

Enochian Biosciences, Inc. (ENOB) Company Bio


Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.


ENOB Latest News Stream


Event/Time News Detail
Loading, please wait...

ENOB Latest Social Stream


Loading social stream, please wait...

View Full ENOB Social Stream

Latest ENOB News From Around the Web

Below are the latest news stories about Enochian Biosciences Inc that investors may wish to consider to help them evaluate ENOB as an investment opportunity.

Enochian BioSciences, Inc.: Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors

LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today

FinanzNachrichten | December 3, 2021

Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors

LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, Inventor and Co-Founder of Enochian BioSciences, and Founder and Director of Seraph Research Institute (SRI), presented new data and announced a partnership between Enochian and Dr. Anahid Jewett, a leader in tumor immunology and cell and gene therapy, on pancreatic cancer, as well as a combined effort with SRI and Enochian on Glioblastoma.

Intrado Digital Media | December 3, 2021

Vanguard Group Inc. Sells 52,662 Shares of Enochian Biosciences, Inc. (NASDAQ:ENOB)

Vanguard Group Inc. reduced its stake in Enochian Biosciences, Inc. (NASDAQ:ENOB) by 16.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 273,656 shares of the companys stock after selling 52,662 shares during the period. Vanguard Group Inc.s holdings in Enochian Biosciences were worth []

Transcript Daily | November 27, 2021

Enochian Biosciences (NASDAQ:ENOB) Shares Up 6.6%

Enochian Biosciences, Inc. (NASDAQ:ENOB)s share price shot up 6.6% on Wednesday . The stock traded as high as $10.00 and last traded at $10.00. 1,000 shares were traded during mid-day trading, a decline of 99% from the average session volume of 198,485 shares. The stock had previously closed at $9.38. The company has a debt-to-equity []

Transcript Daily | November 12, 2021

Bank of New York Mellon Corp Lowers Stock Position in Enochian Biosciences, Inc. (NASDAQ:ENOB)

Bank of New York Mellon Corp lowered its position in Enochian Biosciences, Inc. (NASDAQ:ENOB) by 78.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 11,377 shares of the companys stock after selling 40,638 shares during the period. Bank of New York Mellon Corps holdings in Enochian Biosciences were worth $57,000 as of its most []

Transcript Daily | November 10, 2021

Read More 'ENOB' Stories Here

ENOB Price Returns

1-mo -17.63%
3-mo N/A
6-mo -40.55%
1-year 63.45%
3-year -2.34%
5-year N/A
YTD -14.13%
2021 147.12%
2020 -41.24%
2019 -28.29%
2018 47.37%
2017 216.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1423 seconds.